Published in Antimicrob Agents Chemother on June 14, 2010
Atypical and classical memory B cells produce Plasmodium falciparum neutralizing antibodies. J Exp Med (2013) 1.31
A chemical genomic analysis of decoquinate, a Plasmodium falciparum cytochrome b inhibitor. ACS Chem Biol (2011) 1.31
An Invitation to Open Innovation in Malaria Drug Discovery: 47 Quality Starting Points from the TCAMS. ACS Med Chem Lett (2011) 1.18
Identification of MMV malaria box inhibitors of plasmodium falciparum early-stage gametocytes using a luciferase-based high-throughput assay. Antimicrob Agents Chemother (2013) 1.18
Integrated dataset of screening hits against multiple neglected disease pathogens. PLoS Negl Trop Dis (2011) 1.03
Evaluation of bioluminescence-based assays of anti-malarial drug activity. Malar J (2013) 0.93
Validating a firefly luciferase-based high-throughput screening assay for antimalarial drug discovery. Assay Drug Dev Technol (2011) 0.92
Antiparasitic chemotherapy: from genomes to mechanisms. Annu Rev Pharmacol Toxicol (2013) 0.88
Cyclopropyl Carboxamides: A New Oral Antimalarial Series Derived from the Tres Cantos Anti-Malarial Set (TCAMS). ACS Med Chem Lett (2011) 0.86
An improved single-step lysis protocol to measure luciferase bioluminescence in Plasmodium falciparum. Malar J (2012) 0.85
CRIMALDDI: platform technologies and novel anti-malarial drug targets. Malar J (2013) 0.85
Plasmodium serine hydroxymethyltransferase as a potential anti-malarial target: inhibition studies using improved methods for enzyme production and assay. Malar J (2012) 0.84
Drug repositioning as a route to anti-malarial drug discovery: preliminary investigation of the in vitro anti-malarial efficacy of emetine dihydrochloride hydrate. Malar J (2013) 0.83
Plasmodium falciparum transfected with ultra bright NanoLuc luciferase offers high sensitivity detection for the screening of growth and cellular trafficking inhibitors. PLoS One (2014) 0.82
Discovery of New Compounds Active against Plasmodium falciparum by High Throughput Screening of Microbial Natural Products. PLoS One (2016) 0.78
"Omics"-Informed Drug and Biomarker Discovery: Opportunities, Challenges and Future Perspectives. Proteomes (2016) 0.78
An ultrasensitive NanoLuc-based luminescence system for monitoring Plasmodium berghei throughout its life cycle. Malar J (2016) 0.78
A high-content phenotypic screen reveals the disruptive potency of quinacrine and 3',4'-dichlorobenzamil on the digestive vacuole of Plasmodium falciparum. Antimicrob Agents Chemother (2013) 0.77
High content live cell imaging for the discovery of new antimalarial marine natural products. BMC Infect Dis (2012) 0.77
Enlightening the malaria parasite life cycle: bioluminescent Plasmodium in fundamental and applied research. Front Microbiol (2015) 0.76
Synthesis, spectroscopic characterization, in-vitro antibacterial and antiproliferative activities of some metal(II) complexes of 3,4-dihydronaphthalen-1(2H)-one Schiff base. EXCLI J (2012) 0.75
Investigating antimalarial drug interactions of emetine dihydrochloride hydrate using CalcuSyn-based interactivity calculations. PLoS One (2017) 0.75
Development of a genetic tool for functional screening of anti-malarial bioactive extracts in metagenomic libraries. Malar J (2015) 0.75
An alternative paradigm for the role of antimalarial plants in Africa. ScientificWorldJournal (2012) 0.75
In Vitro Activity of Diphenyleneiodonium toward Multidrug-Resistant Helicobacter pylori Strains. Gut Liver (2017) 0.75
The global distribution of clinical episodes of Plasmodium falciparum malaria. Nature (2005) 31.73
Quantitative assessment of antimalarial activity in vitro by a semiautomated microdilution technique. Antimicrob Agents Chemother (1979) 17.49
Simple and inexpensive fluorescence-based technique for high-throughput antimalarial drug screening. Antimicrob Agents Chemother (2004) 7.51
Chemical genetics of Plasmodium falciparum. Nature (2010) 5.52
Pharmacological evaluation of cimetidine, a new histamine H2-receptor antagonist, in healthy man. Br J Clin Pharmacol (1975) 5.02
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen. Proc Natl Acad Sci U S A (2008) 4.80
High-throughput screening assays for the identification of chemical probes. Nat Chem Biol (2007) 4.50
The past, present and future of childhood malaria mortality in Africa. Trends Parasitol (2001) 4.10
Mutations in dihydropteroate synthase are responsible for sulfone and sulfonamide resistance in Plasmodium falciparum. Proc Natl Acad Sci U S A (1997) 3.61
Mutations in Plasmodium falciparum cytochrome b that are associated with atovaquone resistance are located at a putative drug-binding site. Antimicrob Agents Chemother (2000) 3.58
Assessment and continued validation of the malaria SYBR green I-based fluorescence assay for use in malaria drug screening. Antimicrob Agents Chemother (2007) 3.08
Site of action of the antimalarial hydroxynaphthoquinone, 2-[trans-4-(4'-chlorophenyl) cyclohexyl]-3-hydroxy-1,4-naphthoquinone (566C80). Biochem Pharmacol (1992) 2.74
A clinical drug library screen identifies astemizole as an antimalarial agent. Nat Chem Biol (2006) 2.72
High-throughput Plasmodium falciparum growth assay for malaria drug discovery. Antimicrob Agents Chemother (2006) 2.70
Resistance mutations reveal the atovaquone-binding domain of cytochrome b in malaria parasites. Mol Microbiol (1999) 2.69
The malaria parasite type II NADH:quinone oxidoreductase: an alternative enzyme for an alternative lifestyle. Trends Parasitol (2007) 2.54
Plasmodium falciparum var genes are regulated by two regions with separate promoters, one upstream of the coding region and a second within the intron. J Biol Chem (2003) 2.16
Searching for new antimalarial therapeutics amongst known drugs. Chem Biol Drug Des (2006) 2.10
Target assessment for antiparasitic drug discovery. Trends Parasitol (2007) 1.96
Studies on cytochrome oxidase. 8. Preparation and some properties of cardiac cytochrome oxidase. J Biol Chem (1972) 1.84
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum. Nat Chem Biol (2009) 1.52
Development and validation of flow cytometric measurement for parasitemia in cultures of P. falciparum vitally stained with YOYO-1. Cytometry A (2007) 1.49
A comparison of assay performance measures in screening assays: signal window, Z' factor, and assay variability ratio. J Biomol Screen (2006) 1.34
Mutations in the cytochrome b gene of Plasmodium berghei conferring resistance to atovaquone. Mol Biochem Parasitol (1999) 1.31
Acridinediones: selective and potent inhibitors of the malaria parasite mitochondrial bc1 complex. Mol Pharmacol (2008) 1.22
Functional characterization and target validation of alternative complex I of Plasmodium falciparum mitochondria. Antimicrob Agents Chemother (2006) 1.21
Human disease-related mutations in cytochrome b studied in yeast. J Biol Chem (2004) 1.11
Chapter 17 Type II NADH: quinone oxidoreductases of Plasmodium falciparum and Mycobacterium tuberculosis kinetic and high-throughput assays. Methods Enzymol (2009) 1.01
Kinetic characterization and molecular docking of a novel, potent, and selective slow-binding inhibitor of human cathepsin L. Mol Pharmacol (2008) 1.00
Plasmodium falciparum: development of a transgenic line for screening antimalarials using firefly luciferase as the reporter. Exp Parasitol (2008) 0.98
2-(Aminomethyl)phenols, a new class of saluretic agents. 1. Effects of nuclear substitution. J Med Chem (1980) 0.97
Aminoalkylphenols as antimalarials (heterocyclicamino)-alpha-amino-o-cresols; the synthesis of camoquin. J Am Chem Soc (1948) 0.93
Thin sow syndrome (TSS): the effect of amperozide. Br Vet J (1990) 0.79
Modulation of morphine antinociception by the brain-penetrating H2 antagonist zolantidine: detailed characterization in five nociceptive test systems. Pharmacol Biochem Behav (1995) 0.78
N-Dialkylaminoalkylbiphenylamines as antimalarial and antischistosomal agents. J Med Chem (1969) 0.78
Structural basis for the function and inhibition of an influenza virus proton channel. Nature (2008) 5.69
Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis. Cancer Cell (2004) 4.38
Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry. Proc Natl Acad Sci U S A (2005) 4.07
Folding of helical membrane proteins: the role of polar, GxxxG-like and proline motifs. Curr Opin Struct Biol (2004) 3.42
Activation of integrin alphaIIbbeta3 by modulation of transmembrane helix associations. Science (2003) 3.22
Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction. Blood (2008) 3.11
Plasmodium falciparum: sacrificing membrane to grow crystals? Trends Parasitol (2003) 2.96
Foldamers as versatile frameworks for the design and evolution of function. Nat Chem Biol (2007) 2.79
The molecular mechanism of action of artemisinin--the debate continues. Molecules (2010) 2.57
The malaria parasite type II NADH:quinone oxidoreductase: an alternative enzyme for an alternative lifestyle. Trends Parasitol (2007) 2.54
Structure and mechanism of proton transport through the transmembrane tetrameric M2 protein bundle of the influenza A virus. Proc Natl Acad Sci U S A (2010) 2.43
Helix formation via conformation diffusion search. Proc Natl Acad Sci U S A (2002) 2.34
Identification of the functional core of the influenza A virus A/M2 proton-selective ion channel. Proc Natl Acad Sci U S A (2009) 2.32
Using nitrile-derivatized amino acids as infrared probes of local environment. J Am Chem Soc (2003) 2.30
Computational design of peptides that target transmembrane helices. Science (2007) 2.28
Comparison of PSGL-1 microbead and neutrophil rolling: microvillus elongation stabilizes P-selectin bond clusters. Biophys J (2002) 2.06
Hierarchical organization in the hemostatic response and its relationship to the platelet-signaling network. Blood (2013) 2.05
Substrate profiling of cysteine proteases using a combinatorial peptide library identifies functionally unique specificities. J Biol Chem (2006) 2.05
Evidence for a central role for PfCRT in conferring Plasmodium falciparum resistance to diverse antimalarial agents. Mol Cell (2004) 2.02
Coartem (artemether-lumefantrine) in Africa: the beginning of the end? J Infect Dis (2005) 2.00
Selectin-like kinetics and biomechanics promote rapid platelet adhesion in flow: the GPIb(alpha)-vWF tether bond. Biophys J (2002) 1.97
Distinct protein classes including novel merozoite surface antigens in Raft-like membranes of Plasmodium falciparum. J Biol Chem (2005) 1.95
De novo design of biomimetic antimicrobial polymers. Proc Natl Acad Sci U S A (2002) 1.95
Multiscale prediction of patient-specific platelet function under flow. Blood (2012) 1.93
Molecular dynamics calculations suggest a conduction mechanism for the M2 proton channel from influenza A virus. Proc Natl Acad Sci U S A (2009) 1.93
Amphiphilic polymethacrylate derivatives as antimicrobial agents. J Am Chem Soc (2005) 1.84
Use of thiol-disulfide equilibria to measure the energetics of assembly of transmembrane helices in phospholipid bilayers. Proc Natl Acad Sci U S A (2003) 1.82
Apicomplexan parasites co-opt host calpains to facilitate their escape from infected cells. Science (2009) 1.77
Protein-protein interactions in the membrane: sequence, structural, and biological motifs. Structure (2008) 1.75
Pentamidine uptake and resistance in pathogenic protozoa: past, present and future. Trends Parasitol (2003) 1.74
Computational de novo design, and characterization of an A(2)B(2) diiron protein. J Mol Biol (2002) 1.71
A molecular signaling model of platelet phosphoinositide and calcium regulation during homeostasis and P2Y1 activation. Blood (2008) 1.69
Dimerization of the transmembrane domain of Integrin alphaIIb subunit in cell membranes. J Biol Chem (2004) 1.65
Defining the role of PfCRT in Plasmodium falciparum chloroquine resistance. Mol Microbiol (2005) 1.64
Determining the orientation of uniaxially rotating membrane proteins using unoriented samples: a 2H, 13C, AND 15N solid-state NMR investigation of the dynamics and orientation of a transmembrane helical bundle. J Am Chem Soc (2007) 1.63
The hydration of amides in helices; a comprehensive picture from molecular dynamics, IR, and NMR. Protein Sci (2003) 1.62
Computational design and characterization of a monomeric helical dinuclear metalloprotein. J Mol Biol (2003) 1.60
De novo design and in vivo activity of conformationally restrained antimicrobial arylamide foldamers. Proc Natl Acad Sci U S A (2009) 1.58
Ultrafast folding of alpha3D: a de novo designed three-helix bundle protein. Proc Natl Acad Sci U S A (2003) 1.57
A cathepsin B-like protease is required for host protein degradation in Trypanosoma brucei. J Biol Chem (2004) 1.57
Structural and dynamic mechanisms for the function and inhibition of the M2 proton channel from influenza A virus. Curr Opin Struct Biol (2011) 1.56
Computational de novo design and characterization of a four-helix bundle protein that selectively binds a nonbiological cofactor. J Am Chem Soc (2005) 1.52
Recent highlights in antimalarial drug resistance and chemotherapy research. Trends Parasitol (2008) 1.52
A new method for determining the local environment and orientation of individual side chains of membrane-binding peptides. J Am Chem Soc (2004) 1.51
pH-induced conformational change of the influenza M2 protein C-terminal domain. Biochemistry (2008) 1.48
Computational design of virus-like protein assemblies on carbon nanotube surfaces. Science (2011) 1.45
The kinetics of αIIbβ3 activation determines the size and stability of thrombi in mice: implications for antiplatelet therapy. Blood (2010) 1.40
Salt bridges: geometrically specific, designable interactions. Proteins (2011) 1.39
Sequence determinants of the energetics of folding of a transmembrane four-helix-bundle protein. Proc Natl Acad Sci U S A (2002) 1.39
The interplay of functional tuning, drug resistance, and thermodynamic stability in the evolution of the M2 proton channel from the influenza A virus. Structure (2008) 1.38
An artificial di-iron oxo-protein with phenol oxidase activity. Nat Chem Biol (2009) 1.37
Molecular dynamics simulation directed rational design of inhibitors targeting drug-resistant mutants of influenza A virus M2. J Am Chem Soc (2011) 1.37
Cathepsin L occupies a vacuolar compartment and is a protein maturase within the endo/exocytic system of Toxoplasma gondii. Mol Microbiol (2010) 1.36
Structural basis for proton conduction and inhibition by the influenza M2 protein. Protein Sci (2012) 1.36
Sequence determinants of a transmembrane proton channel: an inverse relationship between stability and function. J Mol Biol (2005) 1.35
Pharmacokinetics of decitabine administered as a 3-h infusion to patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Cancer Chemother Pharmacol (2007) 1.35
Generation of quinolone antimalarials targeting the Plasmodium falciparum mitochondrial respiratory chain for the treatment and prophylaxis of malaria. Proc Natl Acad Sci U S A (2012) 1.34
Design of a switchable eliminase. Proc Natl Acad Sci U S A (2011) 1.34
Long-range interactions stabilize the fold of a non-natural oligomer. J Am Chem Soc (2002) 1.33
Consensus motif for integrin transmembrane helix association. Proc Natl Acad Sci U S A (2009) 1.33
PfCRT and the trans-vacuolar proton electrochemical gradient: regulating the access of chloroquine to ferriprotoporphyrin IX. Mol Microbiol (2006) 1.33
A membrane-based microfluidic device for controlling the flux of platelet agonists into flowing blood. Lab Chip (2008) 1.32
Computational design of water-soluble analogues of the potassium channel KcsA. Proc Natl Acad Sci U S A (2004) 1.31
Pairwise agonist scanning predicts cellular signaling responses to combinatorial stimuli. Nat Biotechnol (2010) 1.31
Alterations in the intrinsic properties of the GPIbalpha-VWF tether bond define the kinetics of the platelet-type von Willebrand disease mutation, Gly233Val. Blood (2003) 1.31
Microfluidics and coagulation biology. Annu Rev Biomed Eng (2013) 1.30
Identification of specific inhibitors of human RAD51 recombinase using high-throughput screening. ACS Chem Biol (2011) 1.30
Specific binding of adamantane drugs and direction of their polar amines in the pore of the influenza M2 transmembrane domain in lipid bilayers and dodecylphosphocholine micelles determined by NMR spectroscopy. J Am Chem Soc (2011) 1.30
De novo designed synthetic mimics of antimicrobial peptides. Curr Opin Biotechnol (2008) 1.30
Systems biology of coagulation initiation: kinetics of thrombin generation in resting and activated human blood. PLoS Comput Biol (2010) 1.29
Thrombus growth and embolism on tissue factor-bearing collagen surfaces under flow: role of thrombin with and without fibrin. Arterioscler Thromb Vasc Biol (2012) 1.29
Acidification of the malaria parasite's digestive vacuole by a H+-ATPase and a H+-pyrophosphatase. J Biol Chem (2002) 1.28
Discovery of spiro-piperidine inhibitors and their modulation of the dynamics of the M2 proton channel from influenza A virus. J Am Chem Soc (2009) 1.28
De novo design of a single-chain diphenylporphyrin metalloprotein. J Am Chem Soc (2007) 1.28
Tidal surge in the M2 proton channel, sensed by 2D IR spectroscopy. Proc Natl Acad Sci U S A (2011) 1.27
Nontoxic membrane-active antimicrobial arylamide oligomers. Angew Chem Int Ed Engl (2004) 1.26
Blood clots are rapidly assembled hemodynamic sensors: flow arrest triggers intraluminal thrombus contraction. Arterioscler Thromb Vasc Biol (2012) 1.25
The malaria parasite progressively dismantles the host erythrocyte cytoskeleton for efficient egress. Mol Cell Proteomics (2011) 1.24
Proton and cation transport activity of the M2 proton channel from influenza A virus. Proc Natl Acad Sci U S A (2010) 1.24
Computational design of a protein crystal. Proc Natl Acad Sci U S A (2012) 1.23
Acridinediones: selective and potent inhibitors of the malaria parasite mitochondrial bc1 complex. Mol Pharmacol (2008) 1.22
Site-specific hydration status of an amphipathic peptide in AOT reverse micelles. Langmuir (2007) 1.21
Functional characterization and target validation of alternative complex I of Plasmodium falciparum mitochondria. Antimicrob Agents Chemother (2006) 1.21
Identification of novel inhibitors of dietary lipid absorption using zebrafish. PLoS One (2010) 1.20
Modulation of the intracellular accumulation of saquinavir in peripheral blood mononuclear cells by inhibitors of MRP1, MRP2, P-gp and BCRP. AIDS (2005) 1.20
Targeted disruption of Plasmodium falciparum cysteine protease, falcipain 1, reduces oocyst production, not erythrocytic stage growth. Mol Microbiol (2004) 1.19
Inhibiting Plasmodium cytochrome bc1: a complex issue. Curr Opin Chem Biol (2010) 1.19